Arovella Therapeutics Limited (ALA.AX)
AUD 0.08
(1.25%)
AUD 0.08
(1.25%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -25.97 Thousand AUD | 99.13% |
| 2023 | -2.99 Million AUD | -3479.99% |
| 2022 | 88.75 Thousand AUD | 156.54% |
| 2021 | 34.59 Thousand AUD | -89.57% |
| 2020 | 331.72 Thousand AUD | -67.46% |
| 2019 | 1.01 Million AUD | 324.32% |
| 2018 | 240.24 Thousand AUD | -86.22% |
| 2017 | 1.74 Million AUD | 49.48% |
| 2016 | 1.16 Million AUD | 93.77% |
| 2015 | 601.92 Thousand AUD | -76.68% |
| 2014 | 2.58 Million AUD | 209.5% |
| 2013 | 833.88 Thousand AUD | 25.32% |
| 2012 | 665.38 Thousand AUD | 43.09% |
| 2011 | 465.02 Thousand AUD | 3171.38% |
| 2010 | 14.21 Thousand AUD | 128.63% |
| 2009 | -49.65 Thousand AUD | -101.3% |
| 2008 | 3.8 Million AUD | 21.23% |
| 2007 | 3.14 Million AUD | -30.97% |
| 2006 | 4.55 Million AUD | 43.07% |
| 2005 | 3.18 Million AUD | 36.96% |
| 2004 | 2.32 Million AUD | 3610.32% |
| 2003 | 62.61 Thousand AUD | 0.0% |
| 2002 | - AUD | 0.0% |
| 2001 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -1.46 Million AUD | -250.62% |
| 2024 Q3 | 4250.00 AUD | 100.29% |
| 2024 FY | -25.97 Thousand AUD | 99.13% |
| 2024 Q4 | -15.91 Thousand AUD | -474.4% |
| 2024 Q1 | 971.81 Thousand AUD | 166.09% |
| 2023 Q3 | 1723.00 AUD | 100.11% |
| 2023 Q2 | -1.62 Million AUD | -360.25% |
| 2023 Q1 | 623.84 Thousand AUD | 155.68% |
| 2023 FY | -2.99 Million AUD | -3479.99% |
| 2023 Q4 | -1.47 Million AUD | -85444.63% |
| 2022 Q3 | 86.37 Thousand AUD | 105.0% |
| 2022 Q4 | -1.12 Million AUD | -1397.06% |
| 2022 FY | 88.75 Thousand AUD | 156.54% |
| 2022 Q1 | -42 Thousand AUD | 96.13% |
| 2022 Q2 | -1.72 Million AUD | -4016.15% |
| 2021 Q2 | -838.89 Thousand AUD | -813.15% |
| 2021 Q3 | 254.95 Thousand AUD | 130.39% |
| 2021 Q4 | -1.08 Million AUD | -525.54% |
| 2021 FY | 34.59 Thousand AUD | -89.57% |
| 2021 Q1 | 117.63 Thousand AUD | 113.22% |
| 2020 FY | 331.72 Thousand AUD | -67.46% |
| 2020 Q2 | -778.25 Thousand AUD | -727.84% |
| 2020 Q1 | 123.95 Thousand AUD | 119.05% |
| 2020 Q3 | 61.52 Thousand AUD | 107.91% |
| 2020 Q4 | -889.94 Thousand AUD | -1546.5% |
| 2019 Q3 | 97.75 Thousand AUD | -76.46% |
| 2019 Q2 | 415.29 Thousand AUD | 0.0% |
| 2019 Q1 | 415.29 Thousand AUD | 1006.05% |
| 2019 Q4 | -650.76 Thousand AUD | -765.74% |
| 2019 FY | 1.01 Million AUD | 324.32% |
| 2018 Q4 | -45.83 Thousand AUD | -269.81% |
| 2018 Q2 | 124.79 Thousand AUD | 0.0% |
| 2018 FY | 240.24 Thousand AUD | -86.22% |
| 2018 Q1 | 124.79 Thousand AUD | 103.95% |
| 2018 Q3 | 26.99 Thousand AUD | -78.37% |
| 2017 Q4 | -3.15 Million AUD | -887.98% |
| 2017 FY | 1.74 Million AUD | 49.48% |
| 2017 Q3 | 400.86 Thousand AUD | 122.09% |
| 2017 Q2 | 180.5 Thousand AUD | 0.0% |
| 2017 Q1 | 180.5 Thousand AUD | 58.76% |
| 2016 Q1 | 294.16 Thousand AUD | 115.6% |
| 2016 FY | 1.16 Million AUD | 93.77% |
| 2016 Q4 | 113.69 Thousand AUD | 0.0% |
| 2016 Q2 | 294.16 Thousand AUD | -0.0% |
| 2016 Q3 | 113.69 Thousand AUD | -61.35% |
| 2015 FY | 601.92 Thousand AUD | -76.68% |
| 2015 Q4 | 136.43 Thousand AUD | 0.0% |
| 2015 Q3 | 136.43 Thousand AUD | -51.51% |
| 2015 Q2 | 281.39 Thousand AUD | 0.0% |
| 2015 Q1 | 281.39 Thousand AUD | -7.1% |
| 2014 Q2 | 1.01 Million AUD | 0.0% |
| 2014 Q1 | 1.01 Million AUD | 372.36% |
| 2014 FY | 2.58 Million AUD | 209.5% |
| 2014 Q4 | 302.91 Thousand AUD | 0.0% |
| 2014 Q3 | 302.91 Thousand AUD | -70.22% |
| 2013 Q1 | 187.22 Thousand AUD | 0.0% |
| 2013 Q3 | 215.37 Thousand AUD | 15.03% |
| 2013 Q4 | 215.37 Thousand AUD | 0.0% |
| 2013 FY | 833.88 Thousand AUD | 25.32% |
| 2013 Q2 | 187.22 Thousand AUD | 0.0% |
| 2012 FY | 665.38 Thousand AUD | 43.09% |
| 2011 FY | 465.02 Thousand AUD | 3171.38% |
| 2010 FY | 14.21 Thousand AUD | 128.63% |
| 2009 FY | -49.65 Thousand AUD | -101.3% |
| 2008 FY | 3.8 Million AUD | 21.23% |
| 2007 FY | 3.14 Million AUD | -30.97% |
| 2006 FY | 4.55 Million AUD | 43.07% |
| 2005 FY | 3.18 Million AUD | 36.96% |
| 2004 FY | 2.32 Million AUD | 3610.32% |
| 2003 FY | 62.61 Thousand AUD | 0.0% |
| 2002 FY | - AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AdAlta Limited | 1.5 Million AUD | 101.723% |
| Acrux Limited | -1.28 Million AUD | 97.977% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 99.603% |
| BTC Health Limited | 16.36 Thousand AUD | 258.796% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 100.349% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 100.226% |
| Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | 100.033% |
| Biome Australia Limited | 7.66 Million AUD | 100.339% |
| Hexima Limited | - AUD | Infinity% |
| Immutep Limited | 1.44 Million AUD | 101.799% |
| Memphasys Limited | 1606.00 AUD | 1717.621% |
| Neuren Pharmaceuticals Limited | 205.17 Million AUD | 100.013% |
| Noxopharm Limited | -534.81 Thousand AUD | 95.142% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 100.7% |
| Race Oncology Limited | 1.38 Million AUD | 101.869% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 99.878% |
| Starpharma Holdings Limited | 7.65 Million AUD | 100.339% |
| Tissue Repair Ltd | 150.51 Thousand AUD | 117.261% |
| Biotron Limited | -40.49 Thousand AUD | 35.851% |
| Alterity Therapeutics Limited | 3.8 Million AUD | 100.683% |
| CSL Limited | 15.28 Billion AUD | 100.0% |
| EZZ Life Science Holdings Limited | 50.94 Million AUD | 100.051% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | 96.531% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | 91.382% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | 352.616% |
| Patrys Limited | 1.39 Million AUD | 101.863% |
| Orthocell Limited | 3.68 Million AUD | 100.704% |
| Imugene Limited | -5.83 Million AUD | 99.555% |
| PYC Therapeutics Limited | 22.05 Million AUD | 100.118% |
| Proteomics International Laboratories Limited | -1.12 Million AUD | 97.687% |
| Cynata Therapeutics Limited | 2.31 Million AUD | 101.122% |
| Nanollose Limited | -348.95 Thousand AUD | 92.555% |
| Invex Therapeutics Ltd | 1.21 Million AUD | 102.143% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | 71.557% |
| Amplia Therapeutics Limited | 4.01 Million AUD | 100.648% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | 102.076% |
| Nyrada Inc. | -5164.07 AUD | -403.072% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 100.008% |
| Dimerix Limited | 583.47 Thousand AUD | 104.452% |
| PharmAust Limited | -1641.00 AUD | -1483.12% |
| AnteoTech Limited | 460.39 Thousand AUD | 105.643% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | 145.728% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | 92.917% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | 40.68% |
| Actinogen Medical Limited | 9.93 Million AUD | 100.262% |
| Immuron Limited | 3.33 Million AUD | 100.779% |
| Argenica Therapeutics Limited | 2.59 Million AUD | 101.0% |